Codexis (CDXS) Appoints New Board Chair
- Oil steadies on doubts output cut will end global glut
- Western Digital (WDC) Raises Q2 Outlook
- Dollar edges up vs yen as traders eye ECB meeting for cues
- Mondelez Int'l (MDLZ) Seen as Kraft Heinz's (KHC) Next Logical Takeover Target - Credit Suisse
- Foxconn says in preliminary discussions to expand U.S. operations
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Codexis, Inc. (Nasdaq: CDXS) announces that Bernard J. Kelley has been named Chairman of the Board, effective November 29, 2016. Mr. Kelley has served as a Director of Codexis since April 2004. He has succeeded former Board Chairman Thomas Baruch, who will continue as a Director and has been named Codexis Chairman Emeritus, an honorary title to recognize his contributions to the company.
“Bernie’s service on our Board of Directors, as well as his impressive background in pharmaceutical manufacturing along with senior management and financial operations acumen have been instrumental in establishing Codexis as a leader in enzyme development,” said Mr. Baruch. “We are delighted that as Chairman of the Board he will continue to build and guide our strategic vision to grow our current lines of business and to expand into adjacent markets.”
“Tom Baruch has been instrumental in leading the Board since Codexis was formed over fourteen years ago, and most recently oversaw the company’s transformational growth back into the pharmaceutical sector,” said John Nicols, Codexis President and CEO. “On behalf of our entire organization, I want to recognize and thank Tom for his legacy of leadership at Codexis.”
Prior to joining the Codexis Board, Mr. Kelley was President of the Merck Manufacturing Division where he was responsible for chemical, pharmaceutical and biological manufacturing and directed the activities of corporate engineering and global procurement. He also served as a member of the Merck Management Committee through his retirement in 2003. Mr. Kelley previously served as a Director of MAP Pharmaceuticals, Inc., a biotechnology company focused on developing inhalation-based therapies, as well as a Director of Aegis Analytical Corporation, an enterprise software company. He holds a B.S. in engineering from the U.S. Naval Academy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Illumina (ILMN) Names New CFO
- National Commerce (NCOM) Adds New Board Member
- Columbus McKinnon (CMCO) to Acquire STAHL in ~$486M Deal
Create E-mail Alert Related CategoriesManagement Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!